Jon Kroll Bjerregaard

Research output

Research output per year 2019 2019 2021 2021

• 1 Poster
• 1 Journal article

Research output per year

Research output per year

Search results

• 2021

  A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma

  Petersen, P. C., Petersen, L. N., Vogelius, I., Bjerregaard, J. K. & Baeksgaard, L., Jul 2021, In: Acta Oncologica. 60, 7, p. 948-953 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Phase II Trial 100%
  • Oxaliplatin 100%
  • Capecitabine 100%
  • Epirubicin 100%
  • Carboplatin 100%
• 2019

  EP1.08-07 Correlation Between Genetic Profiling and Response in Danish ALK-Positive NSCLC Patients Treated with Crizotinib

  Melchior, L. C., Santoni-Rugiu, E., Sørensen, J. B., Bjerregaard, J. K. & Urbanska, E., Oct 2019.

  Research output: Contribution to conference › Poster › Research › peer-review